US Stock MarketDetailed Quotes

BRTX Biorestorative Therapies

Watchlist
  • 1.550
  • +0.100+6.90%
Close Dec 20 16:00 ET
  • 1.480
  • -0.070-4.52%
Post 20:01 ET
10.73MMarket Cap-1.08P/E (TTM)

Biorestorative Therapies Key Stats

Biorestorative Therapies Q3 2024 Earnings Date

Currency:USDNov 13, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
350.00K
233.60K
-116.40K
Miss Est.
+1040.07%
+660.91%
-33.26%
EPS
-0.43
-0.13
+0.30
Beat Est.
+32.82%
-133.33%
+69.76%
Buy

Dec 22, 2024

Biorestorative Therapies Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 628.000K--
--2024/Q4-- / 475.000K--
Nov 13, 20242024/Q3233.600K / 350.000K--
Aug 13, 20242024/Q289.100K / 15.000K--
May 14, 20242024/Q135.000K / 15.000K--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 628.000K--
--2024/Q4-- / 475.000K--
Nov 13, 20242024/Q3233.600K / 350.000K--
Aug 13, 20242024/Q289.100K / 15.000K--
May 14, 20242024/Q135.000K / 15.000K--

Unlock Free Earnings Estimates

Biorestorative Therapies Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Dec 22, 2024

Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data